Quick Facts

• Targeted Conditions: Management of symptoms related to acid reflux.
• Therapeutic Domains: Assisting with the healing of duodenal and gastric ulcers.
• Core Benefit: Helps to reduce excess stomach acid production.

---

Омез Д (which contains omeprazole, a proton pump inhibitor) is indicated for therapeutic use in conditions characterized by excessive gastric acid secretion. The primary purpose is to help alleviate the symptoms associated with Gastroesophageal Reflux Disease (GERD) in adults and certain pediatric patients, including heartburn and acid regurgitation.

This medication is also utilized to facilitate the healing and short-term management of duodenal ulcers and gastric ulcers. Furthermore, it plays a role in the treatment regimen for erosive esophagitis (acid-related damage to the esophagus) and is approved for maintaining the healing of this condition. It may also be administered with antibiotics to assist in the eradication of H. pylori infection, a factor in reducing the risk of ulcer recurrence. In adults, it is also an option for the long-term management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Population Eligibility and Regulatory Restrictions

The eligibility profile for the Omeprazole/Domperidone combination is defined by formal regulatory classifications, primarily due to the established cardiovascular risk profile associated with the Domperidone component.

Classification	Restricted Population
Absolute Contraindication	Patients with pre-existing cardiac conditions (e.g., congestive heart failure, prolonged QTc interval) or severe electrolyte disturbances (e.g., hypokalaemia) [Source 1.2]
Absolute Contraindication	Patients with moderate or severe hepatic impairment [Source 1.2, 2.3]
Absolute Contraindication	Conditions where gastric motility stimulation is harmful, such as gastro-intestinal haemorrhage or mechanical obstruction [Source 1.2]
Contraindication	Patients with a prolactin-releasing pituitary tumour (prolactinoma) [Source 1.2]
Not Recommended/Not Established	Pediatric patients (children), as safety and efficacy for the combination are not established [Source 3.7]
Restricted Use/Caution	Older adults (over 60 years) require caution, with the lowest effective dose advised due to increased cardiac risk [Source 3.2]
Restricted Use	Pregnancy and Lactation; use is restricted and generally not recommended in breastfeeding due to excretion of Domperidone in milk [Source 1.1, 2.4]

The medicine is therefore generally limited to adults who do not have any of the specific, documented cardiac, hepatic, or gastrointestinal contraindications. Official labeling explicitly prohibits use in these high-risk populations.

Interactions with other medicines and products

Official regulatory information for Омез Д (Omeprazole / Domperidone) establishes specific restrictions based on the drug's two active components, primarily involving metabolic pathways and cardiac risk.

Contraindicated Combinations

Co-administration with Strong and Moderate CYP3A4 Inhibitors (e.g., specific oral antifungals or macrolide antibiotics) is formally contraindicated. This restriction also applies to all Medicines that Prolong the QT Interval due to the increased risk of elevated Domperidone exposure and potential cardiac events.

Pharmacokinetic and Pharmacodynamic Interactions

The Omeprazole component, which inhibits the CYP2C19 enzyme, necessitates caution with certain co-administered medicines. Omeprazole reduces the formation of the active metabolite of Clopidogrel, resulting in a clinically significant pharmacokinetic interaction. Additionally, Omeprazole significantly reduces gastric acidity, which subsequently decreases the absorption and therapeutic effect of Acid-Dependent Absorption Medicines such as Ketoconazole and specific antiretrovirals like Atazanavir.

Other Documented Interactions

Omeprazole may decrease the clearance of drugs metabolized by CYP2C19 (e.g., Diazepam and Cilostazol), potentially increasing their systemic exposure. Regulatory documents also note that the interaction severity, particularly related to the Domperidone risk profile, is heightened in patients with Hepatic Impairment.

How Омез Д Works

Омез Д operates through the selective modulation of two distinct physiological mechanisms: enzyme function for chemical control and receptor signaling for mechanical control.

Enzyme-Mediated Acid Secretion Blockade

The Omeprazole component acts within the gastric acid secretion pathway by forming an irreversible covalent bond with the H^+/ K^+-ATPase enzyme, or gastric proton pump . This mechanism permanently inactivates the transport of hydrogen ions, the final step in acid production, resulting in the suppression of intragastric acidity.

Peripheral Dopamine Receptor Modulation

Domperidone functions as a selective antagonist on peripheral dopamine D2/ D3 receptors in the upper gastrointestinal tract. By blocking the natural inhibitory signaling of dopamine, the mechanism enhances the tone and contraction strength of the smooth muscles. This action leads to accelerated transit of gastric contents and augmentation of lower esophageal sphincter pressure.

Mechanistic Complementarity

The combined mechanisms align with physiological needs requiring simultaneous intervention against chemical and mechanical drivers. This results in the coordinated physiological changes of reduced gastric acidity and accelerated gastrointestinal transit.

Administration Scope: Official Guidelines

The Omeprazole/Domperidone combination is prescribed with specific instructions for administration, reflecting the dual action of its components. Dosing recommendations typically follow a standardized approach based on the therapeutic requirements of the active ingredients.

Route of Administration:	Oral capsule
Standard Adult Dose:	1 capsule (Omeprazole 20 mg / Domperidone 10 mg)
Frequency and Timing:	Twice daily, administered before meals
Course Duration:	Typically prescribed for a short-term course of 4 to 8 weeks

---

Procedural Instructions

The medicine is supplied for oral consumption only in a capsule form, which must be swallowed whole without being chewed, crushed, or opened. This special administration condition is necessary to maintain the integrity and intended release profile of the enteric-coated Omeprazole pellets. The precise timing of administration before meals is a high-level requirement essential for optimal drug activity.

In the event that a dose is missed, the missed dose should be omitted and the next dose taken at its regularly scheduled time; a double dose must not be taken to compensate.

For specific patient populations, the administration pattern requires modification. In cases of severe renal impairment, the dosing frequency for the Domperidone component is reduced to once or twice daily, depending on the severity of the condition. This procedural framework defines the standardized approach to usage.

Research evidence / Overview of Studies for Омез Д

This overview describes the types of research and general findings observed in studies for the Omeprazole-Domperidone combination, according to official and peer-reviewed scientific sources. The text focuses on the structure and limitations of the evidence and does not provide clinical advice or discuss side effects, dosing, or safety.

---

Evidence for Use in Gastroesophageal Reflux Disease (GERD)

Research has explored the context under which the Omeprazole-Domperidone combination was studied in individuals exploring symptomatic changes in individuals with GERD. Studies for this condition primarily include Randomized Controlled Trials (RCTs) and scientific reviews. The research typically focused on adults, often including those who reported that previous acid-suppressing medication alone was not providing sufficient relief.

Studies monitored several endpoints, including patient-reported outcomes describing perceived discomfort, such as the frequency of days without reported heartburn, changes in overall symptom intensity, and study outcomes related to physical discomfort, such as observed changes in the esophageal lining (endoscopic findings). Findings describe patterns observed where the combination group recorded differing symptom score measurements when compared to groups studied with a single acid-suppressing medication. What remains uncertain is the long-term effect of this combination, as follow-up durations were limited, typically focusing on acute treatment phases.

---

Research on Functional Dyspepsia (FD) and Acid Peptic Disease (APD)

Research has also explored conditions characterized by fluctuating or episodic manifestations in the upper digestive tract, such as Functional Dyspepsia (FD) and related acid peptic diseases. Research examined temporary physiological imbalance, specifically relating to outcomes such as abdominal discomfort, nausea, and changes in gastric emptying time (a measure of stomach muscle function). Findings indicate that in some comparative studies, individuals using the combination recorded differing functional and motility-related symptom scores when compared to groups using treatments focusing only on acid suppression.

---

Key Gaps and Remaining Uncertainties

The evidence level for this indication is considered moderate because the research base relies on a mix of prospective trials and retrospective reports, and sample sizes were modest in some instances. Data for certain groups remain insufficient, and comparative evidence is lacking. Overall, research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Common questions about Омез Д (FAQ)

---

Q: What are the common side effects I should look out for?

Official documentation identifies common reactions that may occur with this medication. These generally affect the stomach and digestive system. According to the product information, common side effects may include symptoms such as headache, diarrhea, abdominal pain, nausea, vomiting, gas (flatulence), and dry mouth.

---

Q: What is the standard adult dose for Омез Д?

Regulatory information indicates the combination is typically prescribed for adults to be taken in a standard frequency. This dosing pattern is established within official regulatory guidelines. Regulatory texts also define a maximum daily limit for the Domperidone component due to safety considerations, reinforcing the importance of the prescribed amount.

---

Q: How long does it take for Omeprazole/Domperidone to start working?

The Omeprazole component’s action on acid suppression generally begins soon after administration. However, studies referenced in official regulatory submissions assess the onset of clinical relief over time. Specifically, studies often indicate that significant symptom changes are typically evaluated after about 14 days of therapy.

---

Q: Can I drink alcohol while taking Omeprazole/Domperidone?

Regulatory and official product information commonly includes statements regarding alcohol consumption while using this medication. Alcohol consumption may affect the balance of stomach acid, which could potentially impact the intended effects of the medicine. Furthermore, alcohol may enhance side effects like drowsiness associated with the drug.

How to Store and Dispose of Омез Д?

Proper storage ensures the effectiveness and stability of Омез Д (a combination of omeprazole and domperidone). Store the medicine at room temperature, typically between 20 C and 25 C (68 F and 77 F), away from excessive heat, moisture, and direct light. Keep it in its original container and ensure the cap is tightly closed. Do not store it in the bathroom or near a kitchen sink.

Disposal Guidelines

To dispose of Омез Д, follow local guidelines for unused or expired medication. Do not flush this medication down the toilet or pour it into a drain unless instructed to do so by a drug take-back program. The safest method is often a drug take-back program or disposing of it by mixing it with an unappealing substance (like cat litter or coffee grounds) and placing it in a sealed bag in the trash. Keep all medicines out of the sight and reach of children and pets.